An international team has published a detailed protocol for one of the most ambitious cannabis and mental health studies ever proposed, combining real-time daily tracking with two-year follow-up across multiple countries. Importantly, this is a study blueprint only, and no findings have been produced. Clinicians should watch for eventual results but should not cite this paper as evidence of any cannabis effect.

Cannabis is used by hundreds of millions of people worldwide, yet the evidence base for its mental health effects remains fragmented, ideologically polarized, and methodologically inconsistent. Most existing studies rely on retrospective self-report, collapse all cannabis use into a single category, and study Western recreational users almost exclusively. The Blowing Minds protocol represents an attempt to address these limitations at scale, and if completed, it could substantially change the evidentiary landscape that clinicians navigate when counseling patients about cannabis.

The cannabis and mental health literature suffers from several well-recognized deficiencies. Studies inconsistently measure exposure (frequency, potency, cannabinoid profile, route of administration), rarely distinguish between medicinal and recreational use contexts, and almost never account for the legislative and cultural environment in which cannabis is consumed. The Blowing Minds protocol, published in Comprehensive Psychiatry, was designed explicitly to fill these gaps. The study proposes a longitudinal, cross-cultural, observational cohort comparing recreational and medicinal cannabis users across at least six jurisdictions, including the Netherlands, the United States, Brazil, Canada, and sites in Asia and Africa. The research incorporates a 14-day Experience Sampling Method (ESM) phase in which participants log real-time data on affect, craving, sleep, and cannabis use via mobile phone, paired with comprehensive baseline, one-year, and two-year cognitive and mental health assessments.

The authors state that their approach will be “largely data-driven, focused on untangling the effects of cannabis on mental health, either good or bad.” They explicitly acknowledge ideological polarization in cannabis science and commit to balancing investigation of both harms and benefits. Key outcome variables include affect regulation, cannabis use disorder (CUD) symptoms, cognitive performance, and sleep quality. However, it must be emphasized that this document is a protocol paper only. No participants have been enrolled, no data have been collected, and no findings of any kind are reported. The eventual scientific value of this project depends entirely on execution fidelity, sample sizes achieved, and retention across a two-year international follow-up.

I find it genuinely encouraging that a serious international research group is committing to study both medicinal and recreational cannabis users with the same rigor, and across jurisdictions where the legal and cultural contexts differ so dramatically. The ESM approach is exactly the kind of methodology that cannabis research needs more of, because retrospective surveys miss the moment-to-moment reality of how people actually use cannabis and how it affects their mood, sleep, and thinking. That said, this is a blueprint. There are no results here, and I have seen enough well-designed protocols stall or shrink during execution to keep my expectations cautious.

In my practice, I already individualize cannabis guidance based on the specific patient, their product choices, their mental health history, and the context of their use. I do not need to wait for this study’s results to know that those variables matter. But when the data do arrive, they could provide the kind of population-level evidence that helps me have more precise conversations with patients about what to expect and what to watch for. I will be following this study closely.

For clinicians, this protocol is best understood as a signpost indicating where the field is heading rather than a source of new clinical guidance. The study sits at the very beginning of the research arc: design and registration. Its value right now is primarily methodological. The ESM approach and the deliberate comparison of medicinal versus recreational users within the same longitudinal framework represent meaningful advances over the cross-sectional, single-context designs that dominate the existing literature. Clinicians who follow cannabis research should bookmark this protocol and watch for publications from the Blowing Minds consortium in the coming years.

From a pharmacological perspective, the protocol’s attention to product characteristics, including THC and CBD content, route of administration, and frequency of use, is notable because these variables are the ones most likely to differentiate clinical outcomes and are the same variables that clinicians must evaluate when adjusting cannabis recommendations for individual patients. The study’s observational design means it will never establish causality, but it can generate the kind of nuanced associational data that currently does not exist. For now, the actionable takeaway is straightforward: no clinical practice should change based on this paper, but clinicians should be aware that a rigorous international effort is underway to produce evidence that may eventually inform their counseling.